Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686061 | 0.93 | CYP1A1 (0.48) | LMNAKDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL14686059 | 0.93 | CYP1A1 (0.48) | LMNAKDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL14685936 | 0.93 | CYP1A1 (0.48) | LMNAKDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL14685934 | 0.93 | CYP1A1 (0.48) | LMNAKDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL22882733 | 0.90 | CYP1A2 (0.53) | LMNAKDM4ECYP1A1CYP1A2CYP19A1 | |
| SCHEMBL5110026 | 0.90 | CYP1A2 (0.52) | LMNAKDM4ECYP1A1CYP1A2CYP19A1 | |
| SCHEMBL5110021 | 0.90 | CYP1A2 (0.52) | LMNAKDM4ECYP1A1CYP1A2CYP19A1 | |
| SCHEMBL14686039 | 0.89 | GSK3B (0.57) | KDM4EPTGER4PTGER3PTGER2KMT2A | |
| SCHEMBL14686038 | 0.89 | GSK3B (0.57) | KDM4EPTGER4PTGER3PTGER2KMT2A | |
| SCHEMBL24074957 | 0.88 | LCK (0.55) | LMNAKDM4ECYP1A1CYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | MARS, INCORPORATED (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | MARS, INCORPORATED (US) | 2010-02-25 | — | — | US | disclosed |
| EP-1896443-A1 | PREPARATION OF (+)-CATECHIN, (-)-EPICATECHIN, (-)-CATECHIN, (+)-EPICATECHIN, AND THEIR 5,7,3',4'-TETRA-O-BENZYL ANALOGUES | MARS, INCORPORATED (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002877-A1 | PREPARATION OF (+)-CATECHIN, (-)-EPICATECHIN, (-)-CATECHIN, (+)-EPICATECHIN, AND THEIR 5,7,3',4'-TETRA-O-BENZYL ANALOGUES | MARS, INCORPORATED (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | HAAO, TES, HPD | LMNA 1236/4885KDM4E 263/4885PTGER4 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.